TGF-β regulates DNA methyltransferase expression in prostate cancer, correlates with aggressive capabilities, and predicts disease recurrence

Qiang Zhang*, Lin Chen, Brian T. Helfand, Thomas L. Jang, Vidit Sharma, James Kozlowski, Timothy Michael Kuzel, Lihua J. Zhu, Ximing J. Yang, Borko Javonovic, Yinglu Guo, Scott Lonning, Jay Harper, Beverly A. Teicher, Charles Brendler, Nengwang Yu, William J. Catalona, Chung Lee

*Corresponding author for this work

Research output: Contribution to journalArticle

52 Scopus citations

Abstract

Background: DNA methyltransferase (DNMT) is one of the major factors mediating the methylation of cancer related genes such as TGF-β receptors (TβRs). This in turn may result in a loss of sensitivity to physiologic levels of TGF-β in aggressive prostate cancer (CaP). The specific mechanisms of DNMT's role in CaP remain undetermined. In this study, we describe the mechanism of TGF-β-mediated DNMT in CaP and its association with clinical outcomes following radical prostatectomy. Methodology/Principal Findings: We used human CaP cell lines with varying degrees of invasive capability to describe how TGF-β mediates the expression of DNMT in CaP, and its effects on methylation status of TGF-β receptors and the invasive capability of CaP in vitro and in vivo. Furthermore, we determined the association between DNMT expression and clinical outcome after radical prostatectomy. We found that more aggressive CaP cells had significantly higher TGF-β levels, increased expression of DNMT, but reduced TβRs when compared to benign prostate cells and less aggressive prostate cancer cells. Blockade of TGF-β signaling or ERK activation (p-ERK) was associated with a dramatic decrease in the expression of DNMT, which results in a coincident increase in the expression of TβRs. Blockade of either TGF-β signaling or DNMT dramatically decreased the invasive capabilities of CaP. Inhibition of TGF-β in an TRAMP-C2 CaP model in C57BL/6 mice using 1D11 was associated with downregulation of DNMTs and p-ERK and impairment in tumor growth. Finally, independent of Gleason grade, increased DNMT1 expression was associated with biochemical recurrence following surgical treatment for prostate cancer. Conclusions and Significance: Our findings demonstrate that CaP derived TGF-β may induce the expression of DNMTs in CaP which is associated with methylation of its receptors and the aggressive potential of CaP. In addition, DNMTs is an independent predictor for disease recurrence after prostatectomy, and may have clinical implications for CaP prognostication and therapy.

Original languageEnglish (US)
Article numbere25168
JournalPloS one
Volume6
Issue number9
DOIs
StatePublished - Sep 30 2011

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)
  • General

Fingerprint Dive into the research topics of 'TGF-β regulates DNA methyltransferase expression in prostate cancer, correlates with aggressive capabilities, and predicts disease recurrence'. Together they form a unique fingerprint.

  • Cite this

    Zhang, Q., Chen, L., Helfand, B. T., Jang, T. L., Sharma, V., Kozlowski, J., Kuzel, T. M., Zhu, L. J., Yang, X. J., Javonovic, B., Guo, Y., Lonning, S., Harper, J., Teicher, B. A., Brendler, C., Yu, N., Catalona, W. J., & Lee, C. (2011). TGF-β regulates DNA methyltransferase expression in prostate cancer, correlates with aggressive capabilities, and predicts disease recurrence. PloS one, 6(9), [e25168]. https://doi.org/10.1371/journal.pone.0025168